Asthma Inhaler Device Market Outlook 2018 Top Industry Vendors - GlaxoSmithKline Plc., Merck & Co., Inc., 3M, Aristopharma Ltd., SRS PHARMACEUTICALS PVT. LTD., Intas Pharmaceuticals, Ltd. etc. Comprehensive Analysis and Forecast to 2022

Global Asthma Inhaler Device Market - Key Players

Some of the key players in this market are

GlaxoSmithKline Plc. (U.K)
Merck & Co., Inc. (US)
3M (US)
Aristopharma Ltd. (Bangladesh)
SRS PHARMACEUTICALS PVT. LTD. (India)
Intas Pharmaceuticals, Ltd. (India)

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1653

Global Asthma Inhaler Device Market – Overview

In Asthmatic patients, the inside wall of the airways is swollen or inflamed. The inflammation results in the temporary narrowing of the airways carrying oxygen to the lungs. This causes asthmatic symptoms such as shortness of breath, coughing, wheezing, and chest tightness.

Asthma, in severe cases can cause inability to talk. Asthma is an incurable illness. Having said that, with proper treatment, the disease can be managed. Asthma is being treated with the help of the oral drugs and other therapies. However, the respiratory inhalers have completely changed the way Asthma is treated. With the use of respiratory inhalers, asthma can be managed in a better way and the number of people with reduced symptoms or with controlled symptoms has increased.

The Global Asthma Inhaler Market has been evaluated as steadily growing market and expected that the market will reach high growth figures as per report published by Market Research Future. Asthma inhalers are the devices which are used to control the respiratory conditions by directly inhaling the drug into the respiratory tract. Asthma is a chronic disease of the airways of lungs that causes difficulty in breathing.

Global Asthma Inhaler Device Market - Industry Updates

Feb 2017 BI received expantion of FDA approval of the use of Tiotropium Respimat for treatment of Asthma in Children. With this approval, company will be able to sell the product inside the United States.

Jan 2017 AstraZeneca announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. Symbicort is approved in the US to treat asthma in patients 12 years and older and for the maintenance and treatment of COPD in adults, the company is expecting larger market share with the product launch.

Get Discount on Report @ https://www.marketresearchfuture.com/check-discount/1653

Nov 2016 Chiesi acquires Atopix therapeutics. The acquisition of the UK based clinical stage biotechnology company will help Chiesi enhance its Asthma Segment.

Feb 2015 AstraZeneca and Actavis Plc have entered into a definitive agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above certain revenue threshold.

Global Asthma Inhaler Device Market - Segmentation

The Global Asthma Inhaler Device Market is divided into device type, technology, and end-user.

Based on device type, the market is segmented into metered-dose inhaler, MDI with a spacer, dry-powder inhaler, and others.

Based on technology, the market is segmented into manually operated inhaler devices and digitally operated inhaler devices.

Based on end-user, the market is segmented into hospital, clinics, research institutes, and others.

Global Asthma Inhaler Device Market - Regional Analysis

Depending on geographic region, Globally North America is the largest market for Asthma Inhalers. Currently there are around 6.4% of American suffering from COPD in U.S. and around 5.4 million people suffering from asthma in U.K. This major growth is attributed to the popularity of the dry powder inhalers among population due to its several advantages over Metered Dose Inhalers and other types of inhalers.

Europe is the second-largest market for asthma inhalers. It is observed that almost 70% of the child’s death occurred per year due to respiratory disorders are due to these sudden attacks hence rescue medication or rescue inhalers can serve better to save lots of lives per year.

Asia pacific region is expected to be fastest growing region in respiratory Inhaler market. Middle East & Africa is expected to have limited but steady growth in the market. These countries with the advancement of technology are expected to show large number of cases of asthma and other respiratory disease which remain unnoticed currently.

To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/1653

Major Table of Content

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

Continued….

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.